Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cidara Therapeutics Inc is a biotechnology business based in the US. Cidara Therapeutics shares (CDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cidara Therapeutics employs 79 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.54|
|52-week range||$1.46 - $3.15|
|50-day moving average||$1.98|
|200-day moving average||$1.97|
|Wall St. target price||$6.04|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-16)||N/A|
|1 month (2021-09-27)||-34.47%|
|3 months (2021-07-27)||2.67%|
|6 months (2021-04-27)||-29.68%|
|1 year (2020-10-26)||-48.15%|
|2 years (2019-10-25)||-17.20%|
|3 years (2018-10-26)||3.67|
|5 years (2016-10-26)||9.83|
|Revenue TTM||$41.4 million|
|Gross profit TTM||$-55,950,000|
|Return on assets TTM||-42.4%|
|Return on equity TTM||-163.97%|
|Market capitalisation||$103.9 million|
TTM: trailing 12 months
There are currently 678,257 Cidara Therapeutics shares held short by investors – that's known as Cidara Therapeutics's "short interest". This figure is 4% up from 652,407 last month.
There are a few different ways that this level of interest in shorting Cidara Therapeutics shares can be evaluated.
Cidara Therapeutics's "short interest ratio" (SIR) is the quantity of Cidara Therapeutics shares currently shorted divided by the average quantity of Cidara Therapeutics shares traded daily (recently around 283789.53974895). Cidara Therapeutics's SIR currently stands at 2.39. In other words for every 100,000 Cidara Therapeutics shares traded daily on the market, roughly 2390 shares are currently held short.
However Cidara Therapeutics's short interest can also be evaluated against the total number of Cidara Therapeutics shares, or, against the total number of tradable Cidara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cidara Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cidara Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.014% of the tradable shares (for every 100,000 tradable Cidara Therapeutics shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cidara Therapeutics.
Find out more about how you can short Cidara Therapeutics stock.
We're not expecting Cidara Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Cidara Therapeutics's shares have ranged in value from as little as $1.46 up to $3.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cidara Therapeutics's is 1.3254. This would suggest that Cidara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cidara Therapeutics, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.